Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

Extension of RCT (n=566) found long-acting cabotegravir & rilpivirine continued to be non-inferior vs continuing a standard care regimen in adults with HIV-1 for the maintenance of viral suppression at 96 weeks (3% had >50 HIV RNA copies per mL in both groups).

Source:

The Lancet HIV